Cilostazol: an antiplatelet agent for the neurointerventionist?

Antiplatelet agents are essential for the successful management of patients undergoing a variety of neurointerventional procedures. The most commonly used anti-platelet agents are aspirin, clopidogrel and prasugrel. However, there exist an alternative class of anti-platelet agent that may prove useful for neurointerventionists. In particular a drug called cilostazol may have numerous added advantages above and beyond its antiplatelet effect that may be valuable for our patients. In this short review we aim to highlight some of these potential advantages.

[1]  M. Sasaki,et al.  Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[2]  T. Terada,et al.  Prospective registry of carotid artery stenting in Japan--investigation on device and antiplatelet for carotid artery stenting. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[3]  Y. Ohashi,et al.  Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2 , 2014, Cerebrovascular Diseases.

[4]  Y. Xing,et al.  Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis , 2014, Journal of the Neurological Sciences.

[5]  Q. Bi,et al.  Systematic study of cilostazol on secondary stroke prevention: a meta-analysis , 2013, European Journal of Medical Research.

[6]  T. Taoka,et al.  Effect of Cilostazol in Preventing Restenosis after Carotid Artery Stenting Using the Carotid Wallstent: A Multicenter Retrospective Study , 2012, American Journal of Neuroradiology.

[7]  Y. Kai,et al.  Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS). , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[8]  Yuan Zhang,et al.  Wingspan Stents for the Treatment of Symptomatic Atherosclerotic Stenosis in Small Intracranial Vessels: Safety and Efficacy Evaluation , 2012, American Journal of Neuroradiology.

[9]  I. Seong,et al.  Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). , 2008, Journal of the American College of Cardiology.

[10]  C. Grines,et al.  Coronary Stent Restenosis in Patients Treated With Cilostazol , 2005, Circulation.

[11]  S. Kwon,et al.  Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial Stenosis: The Multicenter Double-Blind Placebo-Controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis , 2005, Stroke.

[12]  J. Gaughan,et al.  Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. , 2003, Journal of vascular surgery.

[13]  K. Schrör.  The pharmacology of cilostazol , 2002, Diabetes, obesity & metabolism.

[14]  Seung‐Jung Park,et al.  Effects of cilostazol on angiographic restenosis after coronary stent placement. , 2000, The American journal of cardiology.

[15]  A. Munakata,et al.  Comparison of the Effects of Acetylsalicylic Acid, Ticlopidine and Cilostazol on Primary Hemostasis Using a Quantitative Bleeding Time Test Apparatus , 2000, Pathophysiology of Haemostasis and Thrombosis.

[16]  J. Crouse,et al.  Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[17]  A. Kashiwagi,et al.  Cilostazol, a cAMP Phosphodiesterase Inhibitor, Attenuates the Production of Monocyte Chemoattractant protein-1 in Response to Tumor Necrosis Factor-α in Vascular Endothelial Cells , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  T. Tani,et al.  Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. , 1990, Thrombosis research.

[19]  A. Matsumura,et al.  Cilostazol reduces restenosis after carotid artery stenting. , 2010, Journal of vascular surgery.